Bio-Bridge Announces Favorable Safety and Immunogenicity Results From Pre-clinical Study of Oral HIV Vaccine; Animal Studies Suggest Vaccine is Safe and Efficacious in Treatment of HIV Business Wire
click here to return to Business Wire main menu
DonateNow
Print this Article


Bio-Bridge Announces Favorable Safety and Immunogenicity Results From Pre-clinical Study of Oral HIV Vaccine; Animal Studies Suggest Vaccine is Safe and Efficacious in Treatment of HIV

Business Wire - June 16, 2006

OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of vaccines with broad preventative and therapeutic applications, today announced that the Beijing Institute of Radiation Medicine has notified the Company that it has completed the planned pre-clinical safety and immunogenicity studies for Bio-Bridge's oral HIV vaccine. In early February, Bio-Bridge Science received encouraging initial results of the pre-clinical trials. Final results show no toxicity was observed in the animals orally administered with the HIV vaccine. There is no indication that vaccine DNA integrates into host genome and passes through placenta barrier. The immunogenicity study in monkeys shows that the vaccine induces HIV-1 gp41-specific serum antibodies (IgG) and intestinal and vaginal antibodies (sIgA). The sera, intestinal and vaginal washings neutralize HIV-1 primary isolate in vitro. The vaccine also induces HIV-1 Gag-specific T cells in the vaccinated monkeys.

"We are very pleased that the Beijing Institute of Radiation Medicine has reported favorable safety and immunogenicity data on our oral HIV vaccine," commented Liang Qiao, M.D., Chairman and CEO of Bio-Bridge Science. "It is a major milestone in the development of our HIV vaccine."

Based on these favorable results, the company is expected to file application for clinical trials with the Chinese FDA in the near future.

About Bio-Bridge Science:

Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy", acted to expedite the approval of domestically produced HIV Vaccines. Bio-Bridge Science's GMP facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform as the HIV vaccine.

Forward Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information and accompanying notes to financial statements.

CONTACT: Bio-Bridge Science

Dr. Liang Qiao, 630-928-0869, bbs@bio-bridge-science.com

or

CEOcast, Inc. for Bio-Bridge Science

Andrew Hellman, 212-732-4300

SOURCE: Bio-Bridge Science, Inc.


060616
BW060611

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .